2022年4月18日简报:上海昨日新增2417+19831例,死亡3例;越南视新冠为普通感冒,重点关注高危人群;美国新增病例7235例,死亡10例

2022-04-18 MedSci整理 MedSci整理

截至北京时间2022年4月17日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过5亿418万例,新增657,035例,达到558,345例。累

、截至北京时间2022年4月18日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎COVID-19)病例超过5亿418万例,新增657,035例,达到558,345例。累计死亡病例622.1万例,达到6,221,426例。新增死亡为1,499例。康复为454,750,826例,重症和危重症病人达到42,623例;全球新冠确诊病例超过100万例的国家和地区达59个,125个国家和地区病例超10万例。昨日报道:2022年4月17日简报:本土累计接种新冠疫苗超33.11亿剂次,多地推动老人接种疫苗和加强针;韩国全面解除保持社交距离措施;中国台湾连续两日新增过千;

上海新增2417例本土确诊和19831例本土无症状,死亡3例

上海市卫健委通报:4月17日0—24时,上海新增本土新冠肺炎确诊病例2417例和无症状感染者19831例,其中853例确诊病例为此前无症状感染者转归,1409例确诊病例和19425例无症状感染者在隔离管控中发现,其余在相关风险人群排查中发现。新增境外输入性新冠肺炎确诊病例3例,均在闭环管控中发现。

2022年4月17日0—24时,新增本土死亡病例3例。

死亡病例1,女性,89岁,合并急性冠脉综合征、冠心病、糖尿病、高血压三级、脑梗,死亡病例2,女性,91岁,合并脑梗后遗症、高血压,死亡病例3,男性,91岁,合并冠心病、高血压,3人入院后转为重症,经全力抢救无效死亡。

香港新增747例新冠肺炎确诊病例

香港特区政府卫生署卫生防护中心17日公布,截至当日零时,香港新增747例确诊的新冠肺炎病例,其中经核酸检测确诊病例446例。香港连续3天录得3位数的确诊病例。

4月16日,新冠病毒快速抗原测试阳性结果人士申报系统接获301例呈报病例。

据香港医管局介绍,过去24小时,有24名确诊患者在公立医院离世。

美国新增超1.1万例确诊病例 夏威夷现新冠重组毒株XE

根据Worldometer实时统计数据,截至北京时间2022年4月18日6时30分左右,美国累计确诊新冠肺炎病例82314636例,累计死亡病例1015451例;与前一日6时30分左右数据相比,美国新增确诊病例11201例,新增死亡病例68例。

当地时间15日,美国夏威夷州卫生部门宣布,在该州发现新冠重组毒株XE。今年初,新冠重组毒株XE在英国被首次发现,它是奥密克戎毒株的亚型BA.1和BA.2的重组毒株,已知最早的样本日期为今年1月19日。

日媒民调:76.8%的日本人担心暴发第7波新冠疫情

据日本共同社17日消息,共同社此次民调以电话形式展开,累计收到1067个有效回答。结果显示,对于可能发生的第7波新冠疫情,回答“感到不安”的日本受访者达76.8%。

越南视新冠为感冒,降为B类传染病

据越南政府3月17日颁布的《2022-2023年新冠肺炎疫情防控计划(第38号决议)》,越南将研究并根据疫情情况,将新冠肺炎从A类传染病名单中移除,划归B类传染病,并据此调整防控措施。根据越南《传染病防治法》规定,A类传染病包括传播速度极快、传播范围广、致死率高或病原体不明的特别危险类疾病; B类传染病包括具有高度传染性并可能导致死亡的危险类传染病。

目前越南动态病死率26日已经降到0.02%,世界卫生组织评价称,越南是世界上疫苗覆盖率较高的国家之一。凭借完成新冠疫苗接种人数占全国总人口的80%的成绩,越南住院新冠患者、危重症患者和死亡率呈下降趋势。这是越南逐步开放经济和旅游活动的先决条件之一。

最近一周,因新冠疫情,越南平均每日死亡24人。

越南同时制定了新冠肺炎疫情防控的两种方案,即方案一:新冠肺炎已成为地方流行病;方案二:做好预防措施,以便在出现新情况时避免陷入被动局面。

越南卫生部预防卫生局局长潘仲嶙教授表示,新冠肺炎疫情防控工作不是一个地方、一个国家,而是在全世界范围进行。

基于世卫组织的研究和科学论据,卫生部门已提出了新冠肺炎疫情防控工作的两种情景方案。

潘仲嶙透露,第一情景:奥密克戎毒性逐渐减弱。此外,随着新冠疫苗免疫接种覆盖面的扩大,感染过新冠病毒后的人群产生免疫力,危重症病例和死亡人数将减少。

按照这种情景,越南将进入新常态,即将新冠肺炎列入流行性疾病名单中。若做好疫情防控工作,生活将逐步恢复正常状态。他说:“我们将精力集中关注高龄老人和伴有严重的基础性疾病等的高危人群”。

美国新增确诊病例7,235

当地时间4月16日,根据worldometers数据,美国美国新增确诊病例7,235例,累计新冠肺炎确诊病例达82,316,348例,新增死亡10例,累计死亡病例达1,015,451例。

不过美国多州放弃检测与数据上报,实际病例可能多与7235例。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1924231, encodeId=87821924231b3, content=<a href='/topic/show?id=a37158322eb' target=_blank style='color:#2F92EE;'>#新增病例#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58322, encryptionId=a37158322eb, topicName=新增病例)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/xkicoVBAnV4HxvdCqC1viaW8wdLQdN9hVP9icgqqDsxC6UVPjfhogdfc2iaU1xNUMVlFl5QicicWrjWQBTsVye5ngOQQ/132, createdBy=f92f2500185, createdName=ms7405317358118777, createdTime=Thu Jan 26 06:54:32 CST 2023, time=2023-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675095, encodeId=21a816e50954d, content=<a href='/topic/show?id=7d321022504e' target=_blank style='color:#2F92EE;'>#高危人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102250, encryptionId=7d321022504e, topicName=高危人群)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e95727161035, createdName=Smile2689, createdTime=Mon Nov 21 21:54:32 CST 2022, time=2022-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924945, encodeId=f4e71924945a9, content=<a href='/topic/show?id=51d359969ac' target=_blank style='color:#2F92EE;'>#普通感冒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59969, encryptionId=51d359969ac, topicName=普通感冒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=754b42, createdName=Luyuxie_9, createdTime=Fri Jun 24 21:54:32 CST 2022, time=2022-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212153, encodeId=84841212153bf, content=小越南都能不断改变策略, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=赛华佗, createdTime=Mon Apr 18 12:06:03 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212090, encodeId=7ebe12120903e, content=已学习已分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231215/ac08b4d4cecf4bd3b9af86e00dcbca38/f6b6a60efd854ff191eb5c611ec7dd12.jpg, createdBy=8afb2071832, createdName=15938038573红旗飘飘, createdTime=Mon Apr 18 08:32:51 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212083, encodeId=afa41212083a4, content=好东西, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb3e8121630, createdName=ms1000000226964317, createdTime=Mon Apr 18 08:09:09 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212129, encodeId=5fb81212129ec, content=已学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5aa78103231, createdName=ms5000002000295435, createdTime=Mon Apr 18 10:57:16 CST 2022, time=2022-04-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1924231, encodeId=87821924231b3, content=<a href='/topic/show?id=a37158322eb' target=_blank style='color:#2F92EE;'>#新增病例#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58322, encryptionId=a37158322eb, topicName=新增病例)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/xkicoVBAnV4HxvdCqC1viaW8wdLQdN9hVP9icgqqDsxC6UVPjfhogdfc2iaU1xNUMVlFl5QicicWrjWQBTsVye5ngOQQ/132, createdBy=f92f2500185, createdName=ms7405317358118777, createdTime=Thu Jan 26 06:54:32 CST 2023, time=2023-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675095, encodeId=21a816e50954d, content=<a href='/topic/show?id=7d321022504e' target=_blank style='color:#2F92EE;'>#高危人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102250, encryptionId=7d321022504e, topicName=高危人群)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e95727161035, createdName=Smile2689, createdTime=Mon Nov 21 21:54:32 CST 2022, time=2022-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924945, encodeId=f4e71924945a9, content=<a href='/topic/show?id=51d359969ac' target=_blank style='color:#2F92EE;'>#普通感冒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59969, encryptionId=51d359969ac, topicName=普通感冒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=754b42, createdName=Luyuxie_9, createdTime=Fri Jun 24 21:54:32 CST 2022, time=2022-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212153, encodeId=84841212153bf, content=小越南都能不断改变策略, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=赛华佗, createdTime=Mon Apr 18 12:06:03 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212090, encodeId=7ebe12120903e, content=已学习已分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231215/ac08b4d4cecf4bd3b9af86e00dcbca38/f6b6a60efd854ff191eb5c611ec7dd12.jpg, createdBy=8afb2071832, createdName=15938038573红旗飘飘, createdTime=Mon Apr 18 08:32:51 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212083, encodeId=afa41212083a4, content=好东西, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb3e8121630, createdName=ms1000000226964317, createdTime=Mon Apr 18 08:09:09 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212129, encodeId=5fb81212129ec, content=已学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5aa78103231, createdName=ms5000002000295435, createdTime=Mon Apr 18 10:57:16 CST 2022, time=2022-04-18, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1924231, encodeId=87821924231b3, content=<a href='/topic/show?id=a37158322eb' target=_blank style='color:#2F92EE;'>#新增病例#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58322, encryptionId=a37158322eb, topicName=新增病例)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/xkicoVBAnV4HxvdCqC1viaW8wdLQdN9hVP9icgqqDsxC6UVPjfhogdfc2iaU1xNUMVlFl5QicicWrjWQBTsVye5ngOQQ/132, createdBy=f92f2500185, createdName=ms7405317358118777, createdTime=Thu Jan 26 06:54:32 CST 2023, time=2023-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675095, encodeId=21a816e50954d, content=<a href='/topic/show?id=7d321022504e' target=_blank style='color:#2F92EE;'>#高危人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102250, encryptionId=7d321022504e, topicName=高危人群)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e95727161035, createdName=Smile2689, createdTime=Mon Nov 21 21:54:32 CST 2022, time=2022-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924945, encodeId=f4e71924945a9, content=<a href='/topic/show?id=51d359969ac' target=_blank style='color:#2F92EE;'>#普通感冒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59969, encryptionId=51d359969ac, topicName=普通感冒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=754b42, createdName=Luyuxie_9, createdTime=Fri Jun 24 21:54:32 CST 2022, time=2022-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212153, encodeId=84841212153bf, content=小越南都能不断改变策略, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=赛华佗, createdTime=Mon Apr 18 12:06:03 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212090, encodeId=7ebe12120903e, content=已学习已分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231215/ac08b4d4cecf4bd3b9af86e00dcbca38/f6b6a60efd854ff191eb5c611ec7dd12.jpg, createdBy=8afb2071832, createdName=15938038573红旗飘飘, createdTime=Mon Apr 18 08:32:51 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212083, encodeId=afa41212083a4, content=好东西, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb3e8121630, createdName=ms1000000226964317, createdTime=Mon Apr 18 08:09:09 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212129, encodeId=5fb81212129ec, content=已学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5aa78103231, createdName=ms5000002000295435, createdTime=Mon Apr 18 10:57:16 CST 2022, time=2022-04-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1924231, encodeId=87821924231b3, content=<a href='/topic/show?id=a37158322eb' target=_blank style='color:#2F92EE;'>#新增病例#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58322, encryptionId=a37158322eb, topicName=新增病例)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/xkicoVBAnV4HxvdCqC1viaW8wdLQdN9hVP9icgqqDsxC6UVPjfhogdfc2iaU1xNUMVlFl5QicicWrjWQBTsVye5ngOQQ/132, createdBy=f92f2500185, createdName=ms7405317358118777, createdTime=Thu Jan 26 06:54:32 CST 2023, time=2023-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675095, encodeId=21a816e50954d, content=<a href='/topic/show?id=7d321022504e' target=_blank style='color:#2F92EE;'>#高危人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102250, encryptionId=7d321022504e, topicName=高危人群)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e95727161035, createdName=Smile2689, createdTime=Mon Nov 21 21:54:32 CST 2022, time=2022-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924945, encodeId=f4e71924945a9, content=<a href='/topic/show?id=51d359969ac' target=_blank style='color:#2F92EE;'>#普通感冒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59969, encryptionId=51d359969ac, topicName=普通感冒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=754b42, createdName=Luyuxie_9, createdTime=Fri Jun 24 21:54:32 CST 2022, time=2022-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212153, encodeId=84841212153bf, content=小越南都能不断改变策略, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=赛华佗, createdTime=Mon Apr 18 12:06:03 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212090, encodeId=7ebe12120903e, content=已学习已分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231215/ac08b4d4cecf4bd3b9af86e00dcbca38/f6b6a60efd854ff191eb5c611ec7dd12.jpg, createdBy=8afb2071832, createdName=15938038573红旗飘飘, createdTime=Mon Apr 18 08:32:51 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212083, encodeId=afa41212083a4, content=好东西, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb3e8121630, createdName=ms1000000226964317, createdTime=Mon Apr 18 08:09:09 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212129, encodeId=5fb81212129ec, content=已学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5aa78103231, createdName=ms5000002000295435, createdTime=Mon Apr 18 10:57:16 CST 2022, time=2022-04-18, status=1, ipAttribution=)]
    2022-04-18 赛华佗

    小越南都能不断改变策略

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1924231, encodeId=87821924231b3, content=<a href='/topic/show?id=a37158322eb' target=_blank style='color:#2F92EE;'>#新增病例#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58322, encryptionId=a37158322eb, topicName=新增病例)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/xkicoVBAnV4HxvdCqC1viaW8wdLQdN9hVP9icgqqDsxC6UVPjfhogdfc2iaU1xNUMVlFl5QicicWrjWQBTsVye5ngOQQ/132, createdBy=f92f2500185, createdName=ms7405317358118777, createdTime=Thu Jan 26 06:54:32 CST 2023, time=2023-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675095, encodeId=21a816e50954d, content=<a href='/topic/show?id=7d321022504e' target=_blank style='color:#2F92EE;'>#高危人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102250, encryptionId=7d321022504e, topicName=高危人群)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e95727161035, createdName=Smile2689, createdTime=Mon Nov 21 21:54:32 CST 2022, time=2022-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924945, encodeId=f4e71924945a9, content=<a href='/topic/show?id=51d359969ac' target=_blank style='color:#2F92EE;'>#普通感冒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59969, encryptionId=51d359969ac, topicName=普通感冒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=754b42, createdName=Luyuxie_9, createdTime=Fri Jun 24 21:54:32 CST 2022, time=2022-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212153, encodeId=84841212153bf, content=小越南都能不断改变策略, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=赛华佗, createdTime=Mon Apr 18 12:06:03 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212090, encodeId=7ebe12120903e, content=已学习已分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231215/ac08b4d4cecf4bd3b9af86e00dcbca38/f6b6a60efd854ff191eb5c611ec7dd12.jpg, createdBy=8afb2071832, createdName=15938038573红旗飘飘, createdTime=Mon Apr 18 08:32:51 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212083, encodeId=afa41212083a4, content=好东西, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb3e8121630, createdName=ms1000000226964317, createdTime=Mon Apr 18 08:09:09 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212129, encodeId=5fb81212129ec, content=已学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5aa78103231, createdName=ms5000002000295435, createdTime=Mon Apr 18 10:57:16 CST 2022, time=2022-04-18, status=1, ipAttribution=)]
    2022-04-18 15938038573红旗飘飘

    已学习已分享

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1924231, encodeId=87821924231b3, content=<a href='/topic/show?id=a37158322eb' target=_blank style='color:#2F92EE;'>#新增病例#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58322, encryptionId=a37158322eb, topicName=新增病例)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/xkicoVBAnV4HxvdCqC1viaW8wdLQdN9hVP9icgqqDsxC6UVPjfhogdfc2iaU1xNUMVlFl5QicicWrjWQBTsVye5ngOQQ/132, createdBy=f92f2500185, createdName=ms7405317358118777, createdTime=Thu Jan 26 06:54:32 CST 2023, time=2023-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675095, encodeId=21a816e50954d, content=<a href='/topic/show?id=7d321022504e' target=_blank style='color:#2F92EE;'>#高危人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102250, encryptionId=7d321022504e, topicName=高危人群)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e95727161035, createdName=Smile2689, createdTime=Mon Nov 21 21:54:32 CST 2022, time=2022-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924945, encodeId=f4e71924945a9, content=<a href='/topic/show?id=51d359969ac' target=_blank style='color:#2F92EE;'>#普通感冒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59969, encryptionId=51d359969ac, topicName=普通感冒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=754b42, createdName=Luyuxie_9, createdTime=Fri Jun 24 21:54:32 CST 2022, time=2022-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212153, encodeId=84841212153bf, content=小越南都能不断改变策略, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=赛华佗, createdTime=Mon Apr 18 12:06:03 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212090, encodeId=7ebe12120903e, content=已学习已分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231215/ac08b4d4cecf4bd3b9af86e00dcbca38/f6b6a60efd854ff191eb5c611ec7dd12.jpg, createdBy=8afb2071832, createdName=15938038573红旗飘飘, createdTime=Mon Apr 18 08:32:51 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212083, encodeId=afa41212083a4, content=好东西, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb3e8121630, createdName=ms1000000226964317, createdTime=Mon Apr 18 08:09:09 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212129, encodeId=5fb81212129ec, content=已学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5aa78103231, createdName=ms5000002000295435, createdTime=Mon Apr 18 10:57:16 CST 2022, time=2022-04-18, status=1, ipAttribution=)]
    2022-04-18 ms1000000226964317

    好东西

    1

    展开1条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=1924231, encodeId=87821924231b3, content=<a href='/topic/show?id=a37158322eb' target=_blank style='color:#2F92EE;'>#新增病例#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58322, encryptionId=a37158322eb, topicName=新增病例)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/xkicoVBAnV4HxvdCqC1viaW8wdLQdN9hVP9icgqqDsxC6UVPjfhogdfc2iaU1xNUMVlFl5QicicWrjWQBTsVye5ngOQQ/132, createdBy=f92f2500185, createdName=ms7405317358118777, createdTime=Thu Jan 26 06:54:32 CST 2023, time=2023-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675095, encodeId=21a816e50954d, content=<a href='/topic/show?id=7d321022504e' target=_blank style='color:#2F92EE;'>#高危人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102250, encryptionId=7d321022504e, topicName=高危人群)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e95727161035, createdName=Smile2689, createdTime=Mon Nov 21 21:54:32 CST 2022, time=2022-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924945, encodeId=f4e71924945a9, content=<a href='/topic/show?id=51d359969ac' target=_blank style='color:#2F92EE;'>#普通感冒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59969, encryptionId=51d359969ac, topicName=普通感冒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=754b42, createdName=Luyuxie_9, createdTime=Fri Jun 24 21:54:32 CST 2022, time=2022-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212153, encodeId=84841212153bf, content=小越南都能不断改变策略, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=赛华佗, createdTime=Mon Apr 18 12:06:03 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212090, encodeId=7ebe12120903e, content=已学习已分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231215/ac08b4d4cecf4bd3b9af86e00dcbca38/f6b6a60efd854ff191eb5c611ec7dd12.jpg, createdBy=8afb2071832, createdName=15938038573红旗飘飘, createdTime=Mon Apr 18 08:32:51 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212083, encodeId=afa41212083a4, content=好东西, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb3e8121630, createdName=ms1000000226964317, createdTime=Mon Apr 18 08:09:09 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212129, encodeId=5fb81212129ec, content=已学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5aa78103231, createdName=ms5000002000295435, createdTime=Mon Apr 18 10:57:16 CST 2022, time=2022-04-18, status=1, ipAttribution=)]
    2022-04-18 ms5000002000295435

    已学习

    0

相关资讯

章滨云:关于奥密克戎(Omicron)8个防控策略步骤

国内学者章滨云在其微博上发文,针对Omicron疫情防控,提出防控8个步骤的建议。

2022年4月17日简报:本土累计接种新冠疫苗超33.11亿剂次,多地推动老人接种疫苗和加强针;韩国全面解除保持社交距离措施;中国台湾连续两日新增过千;

截至北京时间2022年4月17日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过5亿418万例,新增657,035例,达到558,345例。累

上海4月16日新增本土病例“3238+21582”例(2022.04.17)

上海市卫健委今早(17日)通报:2022年4月16日0—24时,新增本土新冠肺炎确诊病例3238例和无症状感染者21582例,其中1177例确诊病例为此前无症状感染者转归,1754例确诊病

国家卫健委:昨日新增本土确诊病例3529例 本土无症状感染者22626例(2022.04.17)

4月16日0—24时,31个省(自治区、直辖市)和新疆生产建设兵团报告新增确诊病例3529例。其中境外输入病例25例(广西12例,四川4例,广东3例,上海2例,辽宁1例,浙江1例,福建1例

上海4月15日新增本土新冠肺炎确诊病例3590例、无症状感染者19923例,治愈出院3569例,目前有13例重症(2022.04.16)

2022年4月15日0—24时,新增本土新冠肺炎确诊病例3590例和无症状感染者19923例,其中922例确诊病例为此前无症状感染者转归,2311例确诊病例和19428例无症状感染者在隔离

国家卫健委:4月15日新增新冠肺炎本土确诊病例3867例 治愈出院病例2818例(2022.04.16)

4月14日,工作人员在方舱医院指挥部清洁区消杀(新华社记者 金立旺 摄)。